Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1859

1.

Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition.

Ferrarese M, Baroni M, Della Valle P, Spiga I, Poloniato A, D'Angelo A, Pinotti M, Bernardi F, Branchini A.

Haemophilia. 2019 Apr 17. doi: 10.1111/hae.13761. [Epub ahead of print]

PMID:
30994257
2.

[EXPERIENCE IN DIAGNOSTIC ASSAYS FOR HEPARIN-INDUCED THROMBOCYTOPENIA - EXPERIENCE OF A TERTIARY HOSPITAL IN ISRAEL].

Keren-Politansky A, Hoffman R, Nadir Y, Brenner B, Sarig G.

Harefuah. 2019 Mar;158(3):160-164. Hebrew.

PMID:
30916501
3.

Clot Mayhem: A Case of May-Thurner Syndrome.

Ahmad A, Zain MA, Ashfaq AA, Ali Z, Cheema MA.

Cureus. 2019 Jan 16;11(1):e3899. doi: 10.7759/cureus.3899.

4.

Anticoagulant selection for patients with VTE-Evidence from a systematic literature review of network meta-analyses.

Cohen AT, Berger SE, Milenković D, Hill NR, Lister S.

Pharmacol Res. 2019 Mar 21;143:166-177. doi: 10.1016/j.phrs.2019.03.017. [Epub ahead of print] Review.

5.

Recurrent acute coronary syndrome in a patient with right coronary artery ectasia: a case report.

Damay V, Pranata R, Wiharja W.

J Med Case Rep. 2019 Mar 9;13(1):78. doi: 10.1186/s13256-019-1979-x.

6.

XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.

Kreutz R, Mantovani LG, Haas S, Monje D, Schneider J, Bugge JP, Gebel M, Tamm M, Ageno W, Turpie AGG.

Thromb Res. 2019 Apr;176:125-132. doi: 10.1016/j.thromres.2019.02.010. Epub 2019 Feb 13.

7.

[Impact of short-time anticoagulant therapy after selective percutaneous intervention on prognosis of patients with coronary artery disease].

Song Y, Tang XF, Xu JJ, Wang HH, Liu R, Jiang P, Jiang L, Gao LJ, Zhang Y, Song L, Xu LJ, Zhao XY, Gao Z, Chen J, Gao RL, Qiao SB, Yang YJ, Xu B, Yuan JQ.

Zhonghua Xin Xue Guan Bing Za Zhi. 2019 Feb 24;47(2):108-116. doi: 10.3760/cma.j.issn.0253-3758.2019.02.007. Chinese.

PMID:
30818938
8.

High-dose intravenous immunoglobulin to treat spontaneous heparin-induced thrombocytopenia syndrome.

Mohanty E, Nazir S, Sheppard JI, Forman DA, Warkentin TE.

J Thromb Haemost. 2019 Feb 18. doi: 10.1111/jth.14411. [Epub ahead of print]

PMID:
30773806
9.

Thrombotic complications in inflammatory bowel diseases.

Fornaro R, Caristo G, Stratta E, Caratto M, Caratto E, Giovinazzo D, Di Maira L, Casaccia M, Frascio M.

G Chir. 2019 Jan-Feb;40(1):14-19. Review.

PMID:
30771793
10.

Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients Undergoing Interventional Techniques: American Society of Interventional Pain Physicians (ASIPP) Guidelines.

Kaye AD, Manchikanti L, Novitch MB, Mungrue IN, Anwar M, Jones MR, Helander EM, Cornett EM, Eng MR, Grider JS, Harned ME, Benyamin RM, Swicegood JR, Simopoulos TT, Abdi S, Urman RD, Deer TR, Bakhit C, Sanapati M, Atluri S, Pasupuleti R, Soin A, Diwan S, Vallejo R, Candido KD, Knezevic NN, Beall D, Albers SL, Latchaw RE, Prabhakar H, Hirsch JA.

Pain Physician. 2019 Jan;22(1S):S1-S74.

11.

Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis.

Duffett L, Kearon C, Rodger M, Carrier M.

Thromb Haemost. 2019 Mar;119(3):479-489. doi: 10.1055/s-0039-1677793. Epub 2019 Feb 4.

PMID:
30716777
12.

Comparison of pharmacologic prophylaxis in prevention of venous thromboembolism following total knee arthroplasty.

Richardson SS, Schairer WW, Sculco PK, Bostrom MP.

Knee. 2019 Jan 27. pii: S0968-0160(18)30704-X. doi: 10.1016/j.knee.2019.01.004. [Epub ahead of print]

PMID:
30700390
13.

Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.

Runner RP, Gottschalk MB, Staley CA, Pour AE, Roberson JR.

J Arthroplasty. 2019 Apr;34(4):729-734. doi: 10.1016/j.arth.2018.12.015. Epub 2018 Dec 22.

PMID:
30685257
14.

Fondaparinux in heparin-induced thrombocytopenia: A decade's worth of clinical experience.

Schindewolf M.

Res Pract Thromb Haemost. 2018 Dec 4;3(1):9-11. doi: 10.1002/rth2.12169. eCollection 2019 Jan. No abstract available.

15.

Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 3-Defining antithrombotic protocols.

Blais MC, Bianco D, Goggs R, Lynch AM, Palmer L, Ralph A, Sharp CR.

J Vet Emerg Crit Care (San Antonio). 2019 Jan;29(1):60-74. doi: 10.1111/vec.12795.

PMID:
30654416
16.
17.

The Role of Low Molecular Weight Heparins for Venous Thromboembolism Prevention in Medical Patients-What Is New in 2019?

Haas S.

Hamostaseologie. 2019 Feb;39(1):62-66. doi: 10.1055/s-0038-1677522. Epub 2019 Jan 8.

PMID:
30620990
18.

Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma.

Siriez R, Evrard J, Dogné JM, Pochet L, Bouvy C, Lessire S, Mullier F, Douxfils J.

Int J Lab Hematol. 2019 Apr;41(2):250-261. doi: 10.1111/ijlh.12963. Epub 2019 Jan 3.

PMID:
30604921
19.

Treatment of bleeding complications in patients on anticoagulant therapy.

Piran S, Schulman S.

Blood. 2019 Jan 31;133(5):425-435. doi: 10.1182/blood-2018-06-820746. Epub 2018 Dec 17. Review.

PMID:
30559261
20.

Perioperative Bleeding in Patients With Acute Coronary Syndrome Treated With Fondaparinux Versus Low-Molecular-Weight Heparin Before Coronary Artery Bypass Grafting.

Khodabandeh S, Biancari F, Kinnunen EM, Mariscalco G, Airaksinen J, Gherli R, Gatti G, Demal T, Onorati F, Faggian G, De Feo M, Santarpino G, Rubino AS, Maselli D, Salsano A, Nicolini F, Zanobini M, Ruggieri VG, Bounader K, Perrotti A, Dalén M.

Am J Cardiol. 2019 Feb 15;123(4):565-570. doi: 10.1016/j.amjcard.2018.11.028. Epub 2018 Nov 24.

PMID:
30527774

Supplemental Content

Loading ...
Support Center